Parathyroid tumorigenesis in association with primary hyperparathyroidism

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 1, 2002, Pages 51-60

  Dwight, Trisha ^a   Nelson, Anne E ^a   Marsh, Deborah J ^a   Teh, Bin T ^a   Larsson, Catharina ^a   Robinson, Bruce G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM;

CLINICAL FEATURE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HETEROZYGOSITY LOSS; HUMAN; JAW TUMOR; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; PARATHYROID TUMOR; PRIMARY HYPERPARATHYROIDISM; PROTO ONCOGENE; REVIEW; SIPPLE SYNDROME; SYNDROME; TUMOR SUPPRESSOR GENE;

EID: 0036306263     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200202000-00008     Document Type: Review

References (120)

1. Medical progress-hyperparathyroid and hypoparathyroid disorders
2. Morphology, DNA ploidy and allele losses on chromosome 11 in sporadic hyperparathyroidism and that associated with multiple neoplasia, type 1
3. Familial multiple endocrine neoplasia type 1: A new look at pathophysiology
4. Homozygotes for the autosomal dominant neoplasia syndrome (MEN1)
5. A long-sought needle in the haystack-the multiple endocrine neoplasia type 1 gene
6. Multiple endocrine neoplasia type 1-clinical syndrome to molecular genetics
7. Multiple endocrine neoplasias
8. Parathyroid glands and the multiple endocrine neoplasia syndromes and familial hypocalciuric hypercalcemia
9. The gene for multiple endocrine neoplasia type 1: Recent findings
10. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma
11. Positional cloning of the gene for multiple endocrine neoplasia-type 1
12. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene
13. Menin, the product of the MEN1 gene, is a nuclear protein
14. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
15. Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism
16. Identification and characterization of JunD missense mutants that lack menin binding
17. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling
18. The tumor suppressor protein menin interacts with NF-kappa B proteins and inhibits NF-kappa B-mediated transactivation
19. Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23
20. Characterization of the mouse men 1 gene and its expression during development
21. Menin interacts directly with the homeobox-containing protein Pem
22. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors
23. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states
24. MEN1 gene mutations in 12 MEN1 families and their associated tumors
25. Characterization of mutations in patients with multiple endocrine neoplasia type 1
26. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders
27. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism
28. Identification of MEN1 gene mutations in families with MEN1 and related disorders
29. Criteria for mutation analysis in MEN1-suspected patients: MEN1 case-finding
30. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors
31. Lethality of multiple endocrine neoplasia type 1
32. Phenotype and phenocopy: The relation between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN1)
33. Activation of a novel human transforming gene, RET, by DNA rearrangement
34. Expression of the RET proto-oncogene product in human normal and neoplastic tissues of neural crest origin
35. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
36. RET proto-oncogene mutations in French MEN 2A and FMTC families
37. The relation between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis
38. Mutations of the RET protooncogene in German multiple endocrine neoplasia families - Relation between genotype and phenotype
39. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the ret proto-oncogene
40. Hereditary hyperparathyroidism associated with recurrent pancreatitis
41. Familial cystic parathyroid adenomatosis
42. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: A clinically and genetically distinct syndrome
43. Familial hyperparathyroidism associated with jaw fibroma - Case report and literature review
44. Hereditary hyperparathyroidism jaw tumor syndrome - The endocrine tumor gene HRPT2 maps to chromosome 1q21-q31
45. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease - Linkage to 1 q21-q32 and loss of the wild type allele in renal hamartomas
46. Familial isolated hyperparathyroidism due to multiple adenomas associated with ossifying jaw fibroma and multiple uterine adenomyomatous polyps
47. Hyperparathyroidism-jaw tumor syndrome: The HRPT2 locus is within a 0.7-cM region on chromosome 1q
48. Genetic studies of a family with hereditary hyperparathyroidism jaw tumor syndrome
49. A genotypic and histopathologic study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome
50. Familial isolated hyperparathyroidism - A distinct genetic entity with an increased risk of parathyroid cancer
51. Familial primary hyperparathyroidism complicated with wilms tumor
52. Familial hyperparathyroid syndromes
53. Mapping the gene causing hereditary primary hyperparathyroidism in a Portuguese kindred to chromosome 1q22-q31
54. Genetic mapping of the multiple endocrine neoplasia type 1 locus at 11q13
55. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families
56. Familial hyperparathyroidism without multiple endocrine neoplasia
57. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wildtype alleles in the parathyroid tumors
58. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree
59. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor
60. Familial isolated hyperparathyroidism: Clinical and genetic characteristics of thirty-six kindreds
61. Endocrine effects of lithium: II. Primary hyperparathyroidism
62. Hyperparathyroidism, hypothyroidism, and impaired renal function after 10 to 20 years of lithium treatment
63. Hyperparathyroidism associated with treatment of manic-depressive disorders by lithium
64. Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism
65. Pathology and outcome of surgical treatment for lithium-associated hyperparathyroidism
66. Alternative genetic pathways in parathyroid tumorigenesis
67. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women
68. Multiple adenomas of the parathyroids: Do they exist?
69. Primary hyperparathyroidism associated with two enlarged parathyroid glands
70. Multiple parathyroid adenomas: Report of thirty-three cases
71. Double parathyroid adenomas. Clinical and biochemical characteristics before and after parathyroidectomy
72. Bilateral breast carcinoma: Risk factors and outcomes for patients with synchronous and metachronous disease
73. Primary aldosteronism: Difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands
74. Microsatellite instability and loss of heterozygosity in primary and secondary proliferative lesions of the parathyroid gland
75. The role of hyperplasia in multiple parathyroid adenomas
76. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma
77. Genetic abnormalities in sporadic parathyroid adenomas
78. Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study
79. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: A paraffin immunohistochemical study
80. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice
81. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1
82. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11
83. Allelic loss from chromosome 11 in parathyroid tumors
84. Frequent loss of chromosome arm 1p DNA in parathyroid adenomas
85. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas
86. Somatic mutation of the MEN1 gene in parathyroid tumors
87. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism
88. Alterations of the MEN1 gene in sporadic parathyroid tumors
89. Identification of somatic mutations of the MEN1 gene in sporadic endocrine tumors
90. Loss of heterozygosity in sporadic parathyroid tumors: Involvement of chromosome 1 and the MEN1 gene locus in 11q13
91. Multiple endocrine neoplasia type 1 (MEN1) gene mutations in a subset of patients with sporadic and familial primary hyperparathyroidism target the coding sequence but spare the promoter region
92. Mutation and cancer: Statistical study of retinoblastoma
93. Localisation of a gene causing endocrine neoplasia to a 4 cM region on chromosome 1p35-p36
94. p53 abnormalities in human parathyroid carcinoma
95. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma
96. Absence of p53 point mutations in parathyroid adenoma and carcinoma
97. Inactivation of retinoblastoma gene in malignant parathyroid growths: A candidate genetic trigger?
98. Allelic loss of the retinoblastoma tumor suppressor gene: A marker for aggressive parathyroid tumors?
99. Familial isolated primary hyperparathyroidism with parathyroid carcinomas: Clinical and molecular features
100. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors
101. Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease
102. Patterns of chromosomal imbalances in parathyroid carcinomas
103. Role of p53 mutations in endocrine tumorigenesis: Mutation detection by polymerase chain reaction-single strand conformation polymorphism
104. Overexpression and genetic abnormality of p53 in parathyroid adenomas
105. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid
106. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism
107. Mutational analysis of the extracellular Ca2+-sensing receptor gene in human parathyroid tumors
108. Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism
109. Decreased expression of calcium-sensing receptor messenger ribonucleic acids in parathyroid adenomas
110. Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca2+ set-point in patients with primary hyperparathyroidism
111. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland
112. Obvious mRNA and protein expression but absence of mutations of the RET proto-oncogene in parathyroid tumors
113. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2
114. Analysis of the RET proto-oncogene in sporadic parathyroid adenomas
115. Comparative genomic hybridization analysis of human parathyroid tumors
116. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas
117. Parathyroid tumor suppressor on 1p - Analysis of the p18 cyclin-dependent kinase inhibitor gene as a candidate
118. RAD51 as a candidate parathyroid tumor suppressor gene on chromosome 15q: Absence of somatic mutations
119. Analysis of the RAD54 gene on chromosome 1p as a potential tumor-suppressor gene in parathyroid adenomas